Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4][12]. Core Viewpoints - The company reported a revenue of 1.798 billion yuan for the first half of 2025, representing an 8.80% year-on-year growth, and a net profit of 516 million yuan, which is a 17.19% increase year-on-year [1]. - The blood products business continues to grow steadily, with a revenue of 1.738 billion yuan, up 7.49% year-on-year, and a net profit of 501.89 million yuan, up 18.51% year-on-year [2]. - The company is actively enhancing its plasma collection capabilities, achieving a total plasma collection of 803.66 tons in the first half of 2025, a 5.23% increase compared to the same period last year [2]. - Revenue from similar drugs is on the rise, with the company's affiliate, Hualan Gene, generating sales of 59 million yuan from Bevacizumab [3]. - The company is advancing its innovative drug development, with several products in various stages of clinical trials [3]. Summary by Sections Performance Review - In the first half of 2025, the company achieved an operating income of 1.798 billion yuan, a year-on-year increase of 8.80%, and a net profit attributable to shareholders of 516 million yuan, up 17.19% year-on-year [1]. Operational Analysis - The blood products segment generated 1.738 billion yuan in revenue, a 7.49% increase year-on-year, with a net profit of 501.89 million yuan, reflecting an 18.51% growth [2]. - The company has successfully established a new plasma collection station in Fengdu County, Chongqing, contributing to a total plasma collection of 803.66 tons, a 5.23% increase year-on-year [2]. Profit Forecast, Valuation, and Rating - The report forecasts the company's net profit for 2025-2027 to be 1.25 billion yuan (+15%), 1.41 billion yuan (+13%), and 1.59 billion yuan (+13%) respectively, with corresponding EPS of 0.68, 0.77, and 0.87 yuan [4].

此外，华兰生物表示，拟向全体股东每10股派发现金红利5元（含税）。 北京商报讯（记者 丁宁）8月27日晚间，华兰生物（002007）发布2025半年度报告显示，公司上半年实 现营业收入17.98亿元，同比增长8.8%；归属净利润5.16亿元，同比增长17.19%。 ...

华兰生物8月27日披露半年报，公司上半年实现营业收入17.98亿元，同比增长8.80%；归属于上市公司 股东的净利润5.16亿元，同比增长17.19%；基本每股收益0.2824元。 ...

Core Viewpoint - Hualan Biological (002007.SZ) reported a revenue of 1.798 billion yuan for the first half of 2025, reflecting a year-on-year growth of 8.80% [1] - The net profit attributable to shareholders reached 516 million yuan, marking a year-on-year increase of 17.19% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 484 million yuan, showing a significant year-on-year growth of 33.41% [1] - Basic earnings per share stood at 0.2824 yuan [1]

格隆汇8月27日丨华兰生物(002007.SZ)公布2025年半年度报告，上半年公司实现营业收入17.98亿元，同 比增长8.80%；归属于上市公司股东的净利润5.16亿元，同比增长17.19%；归属于上市公司股东的扣除 非经常性损益的净利润4.84亿元，同比增长33.41%；基本每股收益0.2824元；拟向全体股东每10股派发 现金红利5元(含税)。 ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-035 华兰生物工程股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 华兰生物工程股份有限公司（以下简称"公司"）于2025年8月27日召开第九届 董事会第二次会议，审议通过了《关于2025年半年度利润分配预案》，该议案尚需 提交公司2025年第二次临时股东会审议。 二、2025年半年度利润分配预案情况 根据公司 2025 年半年度财务报告（未经审计），截至 2025 年 6 月 30 日，公司 合并报表中未分配利润为 7,885,280,035.22 元，母公司报表中未分配利润为人民币 低的原则，截至 2025 年 6 月 30 日，公司可供股东分配的利润为 2,761,106,442.53 元，公司总股本为 1,827,456,666 股。 为切实提升股东回报水平，保持长期积极稳定回报股东的分红策略，根据《公 司法》等法律法规及《公司章程》的有关规定，不影响公司正常经营和持续发展的 情况下，经董事会审议，拟定 2025 年半年度的利润分配方案为：以公司总股本 股，不以 ...

| 编制单位：华兰生物工程股份有限公司 | | | | | | | | | | 单位：元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性 | 资金占用方名称 | 占用方与上市公司 | 上市公司核算的会计科目 | 2025年期初占用资金余额 | 2025年半年度占用累计发 | 2025年半年度占用资金的 | 2025年半度度偿还累计发 | 2025年半年度期末占用资 | 占用形成原因 | 占用性质 | | 资金占用 | | 的关联关系 | | | 生金额（不含利息） | 利息（如有） | 生金额 | 金余额 | | | | 控股股东、实 | | | | | | | | | | 非经营性占用 | | 际控制人及其 附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | — | — | — | | | | | | | — | | 前控股股东、 | | | | | | | | | | 非经营性占用 | | 实际控制人及 其附属企业 | | | | | | | | | | 非经营性占用 | ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-033 华兰生物工程股份有限公司（以下简称"公司"）第九届董事会第二次会议于 2025 年 8 月 15 日以电话或电子邮件方式发出通知，于 2025 年 8 月 27 日下午在公 司办公室三楼以现场加通讯表决的方式召开。 会议由公司董事长安康先生主持。会议应到董事 9 名，实到董事 9 名。会议符 合《公司法》和《公司章程》的规定。 二、董事会会议审议情况 董事会会议审议情况 经与会董事认真审议，形成如下决议： 1、审议通过了《2025年半年度报告及摘要》。 华兰生物工程股份有限公司 第九届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：9票赞成，0票反对，0票弃权。 3、审议通过了《关于召开 2025 年第二次临时股东会的通知》 公司严格按照《证券法》及《深圳证券交易所股票上市规则》等有关规定， 完 成了2025年半年度报告的编制工作。公司董事、高级管理人员对该报告签署了书面 确认意见。 表决结果：9票赞成，0票反对，0票弃权。 2、 ...

每经AI快讯，8月27日，华兰生物(002007.SZ)公告称，公司2025年半年度实现营业收入17.98亿元，同比 增长8.80%；归属于上市公司股东的净利润为5.16亿元，同比增长17.19%。公司拟向全体股东每10股派 发现金红利5元（含税）。 （文章来源：每日经济新闻） ...

Market Overview - The biopharmaceutical sector experienced a decline of 2.85% on August 27, with Kanghua Biotech leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Wuwei Biotech (300357) saw a significant increase of 5.38%, closing at 30.95 with a trading volume of 299,000 shares and a transaction value of 915 million yuan [1] - Kanghua Biotech (300841) reported a notable decline of 8.89%, closing at 76.60 with a trading volume of 125,200 shares and a transaction value of 993 million yuan [2] - Anke Biotech (300009) also faced a drop of 5.59%, closing at 11.14 with a trading volume of 862,300 shares and a transaction value of 990 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 1.853 billion yuan from institutional investors, while retail investors saw a net inflow of 1.543 billion yuan [2] - The capital flow for individual stocks indicates that Hualan Biotech (002007) had a net inflow of 32.28 million yuan from institutional investors, while it faced a net outflow of 40.67 million yuan from speculative funds [3] - The overall trend shows that retail investors are actively investing in the sector despite the institutional outflows [2][3]